H.C. Wainwright reiterated a Buy rating and $15.00 price target on Alpha Tau Medical Ltd. (NASDAQ:DRTS). The stock surged 228% over the last year, trading at $10.68, near its 52-week high of $10.85.
Alpha Tau Medical reported its first-quarter fiscal 2026 results earlier this week. The company posted a net loss of $22.9 million, or $0.26 per share. Analysts maintain a Strong Buy consensus with price targets ranging from $8 to $17, though profitability is not expected this year.
The company completed patient enrollment in its U.S. multicenter pivotal ReSTART trial of Alpha DaRT for recurrent cutaneous squamous cell carcinoma. The trial enrolled 88 patients.
Alpha Tau submitted the first module of its modular pre-market approval application in January 2026. Topline data from ReSTART is expected around the end of 2026.
